For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, Representative Director, President and CEO (Code no.: 4568, First Section, Tokyo Stock Exchange) Please address inquiries to Noriaki Ishida, Executive Officer, Vice President, Corporate Communications Department Telephone: +81-3-6225-1126 http://www.daiichisankyo.com/

Daiichi Sankyo's "R&D Day 2015"

Tokyo, Japan (December 14, 2015) - Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) will hold its "R&D Day 2015" at its Tokyo headquarters at 3pm JST on Monday, December 14, 2015.

Dr. Glenn Gormley, Senior Executive Officer and Global R&D Head, will give a briefing about Daiichi Sankyo research and development activities to media, security analysts, and institutional investors. Topics will include an update on Daiichi Sankyo's late stage innovative product pipeline and its R&D strategies for oncology.

Following the event, a video of "R&D Day 2015" will be available on the Daiichi Sankyo corporate website via the following link: http://www.daiichisankyo.com/media_investors/investor_relations/ir_calendar/detail/005286.html)

Attachment: presentation material

Passion for Innovation. Compassion for Patients.™





December 14 2015

Research and Development at Daiichi Sankyo

Glenn Gormley MD PhD

Senior Executive Officer, Global R&D Head

Daiichi Sankyo Co., Ltd.


Agenda



- Pipeline overview
- Pipeline update : Thrombosis, Diabetes and Pain
- Focus on Oncology

R&D Focus Therapeutic Areas





*Discovery: Research and Early Development up to Proof of Concept

Major R&D pipeline


As of October 2015



Therapeutic area	Phase 1	Phase 2	Phase 3	Application
Cardio vascular- Metabolics	 DS-1040 (Acute ischemic stroke / TAFia inhibitor) DS-8312 (Hypertriglyceridemia) DS-2330 (Hyperphosphatemia) DS-9231/TS23 (Thrombosis / α2-PI inactivating antibody) 	 CS-3150 (JP) (Hypertension · DM nephropathy / MR antagonist) DS-8500 (JP) (Diabetes / GPR119 agonist) 	 Prasugrei (JP) (CS-747 / Ischemic stroke / anti- platelet agent) Prasugrei (US) (CS-747 / sickle cell disease / anti- platelet agent) 	 Edoxaban (ASCA etc.) (DU-176b / AF / oral factor Xa inhibitor) Edoxaban (ASCA etc.) (DU-176b / VTE / oral factor Xa inhibitor)
Oncology	 DS-3032 (US/JP) U3-1565 (US/JP) (MDM2 inhibitor) PLX7486 (US) (FMS / TRK inhibitor) DS-8895 (JP) (Anti-EPHA2 antibody) DS-8051 (US) (NTRK/ROS1 inhibitor) DS-8273 (US) (Anti-DR5 antibody) DS-5573 (JP) (Anti-B7-H3 antibody) DS-8201 (JP) (Anti-HER2 ADC) 	 Patritumab (US/EU) (U3-1287 / anti-HER3 antibody) Pexidartinib (US) (PLX3397 / FMS/KIT/FLT3-ITD inhibitor) 	 Tivantinib (US/EU) (ARQ 197 / HCC / MET inhibitor) Denosumab (JP) (AMG 162 / breast cancer adjuvant / anti-RANKL antibody) Nimotuzumab (JP) (DE-766 / gastric cancer / anti-EGFR antibody) Vemurafenib (US/EU) (PLX4032 / melanoma adjuvant / BRAF inhibitor) Quizartinib (US/EU) (AC220 / AML / FLT3-ITD inhibitor) Pexidartinib (US/EU) (PLX3397/TGCT / FMS/KIT/FLT3-ITD inhibitor) 	
Others	 DS-1093 (Anemia of chronic kidney disease / HIF-PH inhibitor) DS-3801 (Chronic obstipation / GPR38 agonist) DS-1971 (Chronic pain) DS-1501 (Osteoporosis / Anti-Siglec-15 antibody) DS-7080 (AMD / Angiogenesis inhibitor) VN-0102/JVC-001 (JP) (MMR vaccine) 	 SUN13837 (US/EU) (Spinal cord injury / modulator of bFGF signaling system) Laninamivir (US/EU) (CS-8958 / anti-influenza / out-licensing with Biota) 	 Mirogabalin (US/EU) (DS-5565 / fibromyalgia / α2δ ligand) Mirogabalin (JP/Asia) (DS-5565 / DPNP/ α2δ ligand) Mirogabalin (JP/Asia) (DS-5565 / PHN / α2δ ligand) Denosumab (JP) (AMG 162 / rheumatoid arthritis / anti-RANKL anti-body) Hydromorphone (JP) (DS-7113 / cancer pain / opioid μ-receptor regulator) CHS-0214 (JP) (Etanercept BS / rheumatoid arthritis / TNFa inhibitor) CL-108 (US) (Acute pain / opioid μ-receptor regulator) VN-0105 (JP) (DPT-IPV/Hib vaccine) VN-0107/MEDI3250 (JP) (Nasal spray flu vaccine vaccine) 	 Intradermal Seasonal Influenza Vaccine (JP) (VN-100 /prefilled i.d. vaccine for seasonal flu) VN-101 (JP) (Cell-culture H5N1 Influenza vaccine)

Targets for Approval and Launch






Agenda



- **Pipeline overview**
- Pipeline update : Thrombosis, Diabetes and Pain
- Focus on Oncology


Medical Management of Thrombosis





Opportunity for a new fibrinolysis enhancer






Global sales for alteplase: \$1.1 B in 2014 (Source: EvaluatePharma)

DS-8500 : GPR119 agonist





Mechanism of Action


- Amplify glucose-stimulated insulin secretion
- Improve β-cell function
- Stimulate GLP-1 secretion

- DPP-IV i: Dipeptidyl Peptidase-4 inhibitor
- GLP-1: Glucagon-Like Peptide-1
- PYY: Peptide YY

Results of Phase 2a study are anticipated to be published in 1H 2016

DS-8500 : GPR119 agonist






Subject	T2DM patients
Region	Japan
Study	Primary endpoint: HbA1c
endpoints	Safety: adverse events, hypoglycemia
Study timeline	Nov 2015 (FPI) \sim 4Q FY2016 (TLR anticipated)

FPI: First Patient In TLR: Top Line Results


http://www.clinicaltrials.jp/user/cteSearch_e.jsp JapicCTI-153068





U.S. Pain Market Holds Great Opportunity





Source: Symphony Health PHAST Audit, Encuity

Update on CL-108




Third Phase 3 study recently completed :

- Double-Blind, Active- and Placebo-Controlled study
- Population: 550 patients, with pain after bunionectomy surgery
- Results: co-primary endpoints were met:
 - Pain relief and prevention or reduction of OINV* (both p<0.001)</p>
- Results are planned to be published in 2016

OINV: opioid-induced nausea and vomiting

Mirogabalin: Phase 2, DB Study in DPNP





• 2 doses reached statistical significance versus pregabalin **¶: p<0.05**

American Diabetes Association 74th Scientific Sessions; June 13-17, 2014; San Francisco, California.

West: Mirogabalin Phase 3 FM Study Design



Double-Blind Treatment (300 patients per arm)

Mirogabalin 15 mg QD	Mirogabalin 15 mg QD
Mirogabalin 15 mg QD	Mirogabalin 15 mg BID
Placebo	Placebo
Pregabalin 75 mg BID	Pregabalin 150 mg BID
Titration (1 week)	Maintenance (12 weeks)

 Primary outcome: change from baseline in the ADPS at week 13

> ADPS: Average Daily Pain Score FM: Fibromyalgia


Top Line Results anticipated in 1H 2017

Asia: Peripheral Neuropathic Pain (PNP) Phase 3 Study Design



Double-Blind Treatment

(150 patients per Mirogabalin arm, 300 patients in placebo arm)



Top Line Results anticipated in 1H 2017

Agenda



- Pipeline overview
- **Pipeline update:** Thrombosis, Diabetes and Pain

• Focus on Oncology


Daiichi Sankyo Oncology Strategy



- Focus on FIC opportunities
- Develop Personalized medicine based therapies
- Maintain strong academic partnerships
 - National Cancer Center of Japan
 - UCSF
 - Max Planck
- Partner with innovative biotech companies
 - ArQule
- Strategic acquisitions
 - Plexxikon
 - Ambit

Oncology Clinical Pipeline





DS-8201: Phase 1



Innovative anti-HER2 antibody drug conjugate (ADC)

• DS-8201 compared to T-DM1

		DS-8201	T-DM1
Y	Antibody	HER2 Ab	Trastuzumab
	Conjugated toxin	Topoisomerase I inhibitor	Tubulin inhibitor
	DAR*	7-8	3.5
	*DAR: Drug to An	tibody Ratio	


• Differentiation from T-DM1

- Different conjugated toxin
- Original ADC technology
- Higher drug to antibody ratio

Mechanism of action

- Ab binds HER2 receptor and is internalized
- Conjugated toxin is released inside cell
- Toxin causes targeted cell death

• Patient-derived tumor xenograft models



DS-8201demonstrated potent anti-tumor efficacy against:

T-DM1 insensitive model HER2 weakly-positive model

Next Generation of DS Oncology Portfolio



Immune-oncology

- Immune checkpoint inhibitors
- Cell therapy

Epigenetics


- IDH1 mutant inhibitor
- EZH 1/2 inhibitor

Epigenetic Targeting of Cancer Cells



IDH1 mutant inhibitor and EZH1/2 dual inhibitor

- IDH1 mutant inhibitor decreases 2-hydroxyglutarate (2-HG) and improve transcriptional abnormality
- EZH 1/2 inhibitor decreases histone methylation and increases transcription of tumor suppressor genes
- Clinical studies of both inhibitors planned for 2016







Four novel compounds targeting unique pathways in Phase 2/3 registration trials

Quizartinib (Ph3)

Acute myeloid leukemia (AML)

Pexidartinib (Ph3)

Tenosynovial giant cell tumor (TGCT)

Tivantinib (Ph3)

Hepatocellular carcinoma (HCC) in partnership with ArQule

Patritumab (Ph2/3)

Non-small cell lung cancer (NSCLC)

Passion for Innovation. Compassion for Patients.™

Quizartinib


Investigational FLT3 Inhibitor

Acute Myeloid Leukemia (AML)


Granted Orphan Drug Designation by the FDA and EMA Granted Fast Track Status by the FDA


Quizartinib: a Selective Inhibitor of ITD mutated FLT3 receptor





Reference: Levis M, et al. Leukemia. 2003;17:1738-52.






References: Zarrinkar PP, et al. Blood. 2009;114(14):2984-92. Sexauer A, et al. Blood. 2012;120(20):4205-14.

Reference: Levis M, et al. Leukemia. 2003;17:1738-52.

Acute Myeloid Leukemia




Epidemiology in US




FLT3-ITD mutation: 23% of AML

survival rate lower than patients without this mutation



Paradigm for the Treatment of AML






Quizartinib: Effect in FLT3-ITD(+) AML



Observed Response Rate for specific and non-specific FLT3 Inhibitors Administered as a Single Agent in FLT3-ITD(+) AML


Patients (%) Achieving CRc



Modified from Ambit Presentation & Knapper, S., 2011 and ASCO 2015 28

Quizartinib: QuANTUM-R Phase 3 Study







MEC: mitoxantrone, etoposide, and intermediate-dose cytarabine FLAG-IDA: fludarabine, cytarabine, and granulocyte colony stimulating factor (G-CSF) with idarubicin

https://clinicaltrials.gov/show/NCT02039726

Plans to Maximize Value of Quizartinib











Highly Selective Treatment for Relapsed Refractory AML

- Targeted therapy against ITD mutated FLT3 receptor
- Once daily oral dosing
- Well tolerated outpatient treatment
- Overall survival in Phase 2: 6 months

Pexidartinib : PLX3397


Investigational CSF-1R Inhibitor

Tenosynovial Giant Cell Tumor (TGCT)

Granted Orphan Drug Designation by the FDA and EMA Granted Breakthrough Therapy designation by FDA

No Approved Systemic Therapies for TGCT





Recurrent, diffuse TGCT may require multiple surgeries and even amputation

Early Results in Treatment of TGCT





4 months on pexidartinib






Walking with cane Unable to straighten knee Narcotics for pain Unable to work Amputation considered Walking unassisted Improved range of motion Off narcotics Back to work



Tap et al, ASCO 2014

Efficacy Evaluation by RECIST 1.1 Criteria






PR: Partial Response

Pexidartinib: Phase 3 Study Design





TLR anticipated in 1H 2018

Target Population of Phase 3 Study



Treatable patients in the US, EU and Japan are estimated to be around 38,000

- Often under-diagnosed
- Affected patients have normal life expectancy

High unmet need

- High morbidity
- No systemic therapies approved





Collaboration with Merck :


Pexidartinib in combination with anti-PD-1 therapy for advanced melanoma and multiple other solid tumors



Other potential indications : Glioblastoma Ovarian cancer Breast cancer Sarcomas

Pexidartinib in Combination with anti-PD-1 Therapy for Advanced Solid Tumors







Phase 1 / 2a study outline

	Part 1: Dose-escalation phase	Part 2: Expansion phase
Dose	Pexidartinib: dose escalation + Pembrolizumab: 200 mg every 3wks	Pexidartinib: RP2D + Pembrolizumab: 200 mg every 3wks
Target patients for enrollment	Advanced solid tumors N=24	Advanced melanoma (+ other Solid tumors) N=376
Outcome measures	Primary: Safety during 1 year treatment Secondary: Objective response rate (rate of a complete response or partial response relative to historical control)	

TLR for part 2 anticipated in 2H 2019

Passion for Innovation. Compassion for Patients.™

Tivantinib

Investigational MET Inhibitor for treatment of

Hepatocellular Carcinoma (HCC)






Granted Orphan Drug Designation by FDA and EMA

Liver and Intrahepatic Bile Duct Cancer



Epidemiology in US¹⁾




Tivantinib: Selective, oral MET inhibitor



Role of MET in HCC


- MET is the only receptor for hepatocytegrowth factor (HGF) leading to :
 - Cell survival
 - Cell invasion
 - Cell proliferation

• MET expression is correlated with poor prognosis in patients with HCC



Tivantinib: Phase 2 Study in 2nd line HCC





Endpoints:	
primary:	ТТР
secondary:	PFS, OS, ORR
tertiary:	TTP, PFS, OS in subgroups by MET Diagnostic status (high vs low levels)

Successful Results of the Phase 2 Study



Treatment with Tivantinib met the primary endpoint of the study, with a 56% improvement in TTP (data not shown here)

• TTP: HR=0.64 p=0.04

- Pronounced benefit was observed in patients with high expression of MET
 - TTP: HR = 0.43 p= 0.03
 - OS: HR = 0.38 p= 0.01
- These are the first randomized data in HCC showing OS advantage with a MET inhibitor and identifying a subgroup responding to a targeted therapy





Figure 4: Kaplan-Meier estimate of time to progression (A) and overall survival (B) in the MET-high subgroup Squares and circles represent censoring of data.

Tivantinib: METIV-HCC Phase 3 design





Endpoints:

primary: OS secondary: PFS, safety

TLR anticipated in 1H 2017

Patritumab


Investigational Anti-HER3 Monoclonal Antibody Non-Small Cell Lung Cancer (NSCLC) Head and Neck Cancer (H&N)



Lung and Bronchial Cancer




Epidemiology in US¹⁾




1) http://seer.cancer.gov/statfacts/html/alyl.html accessed 17 Nov 2015

The HER Family (human epidermal growth factor receptors)



Unique Property of HER3: Escape from Growth Inhibition associated with Current Treatments




Phase 2: HERALD Study Design




Subjects with Advanced NSCLC Who Have Progressed on at Least One Prior Chemotherapy

• Biomarker Hypothesis : Patritumab will have the greatest benefit in patients with high expression of the HER3 ligand heregulin



HERALD: PFS in patients with High levels of Heregulin






Biomarker positive group showed significant improvement in PFS

Joachim von Pawel et al. ASCO Annual Meeting 2014

Patritumab: HER3 Lung Trial




2 Part Phase 2b / 3 Study



TLR (Part B) anticipated in 2H 2018

Patritumab: Head & Neck Cancer Indication





- Patients: R/M Head and Neck Cancer 1st Line
- Cetuximab + Platinum chemo+ Patritumab
- Enrollment completed
- Results will be published in 1H 2016


Phase 2 (n=105)

- Enrollment to begin December 2015
- 2:1 randomization: high vs low HRG

Launch Timeline of DS Pipeline in Oncology







Passion for Innovation. Compassion for Patients.™



Thank you

Contact address regarding this material

Daiichi Sankyo Co., Ltd. Corporate Communications Department

TEL: +81-3-6225-1126

Financial forecasts, future projections and R&D information that Daiichi Sankyo discloses may include information that might be classified as "Forward Looking Statement". These forward looking statements represent our current assumptions basis on information currently available. Please note that such are subject to a number of known and unknown risk and uncertainties and our future performance may differ from the expectations as expressed in such statements.